Ola Engkvist

Jul 4, 2024 | nature.com | Aled Edwards |Ola Engkvist |David G. Hulcoop |Andrew Leach |Brian D. Marsden |Amelie Menge | +10 more

AbstractThe Structural Genomics Consortium is an international open science research organization with a focus on accelerating early-stage drug discovery, namely hit discovery and optimization. We, as many others, believe that artificial intelligence (AI) is poised to be a main accelerator in the field. The question is then how to best benefit from recent advances in AI and how to generate, format and disseminate data to enable future breakthroughs in AI-guided drug discovery.